← Back to all trials
Completed
NCT05750602
Combined Effect of LIMICOL and Physical Activity on LDL Cholesterol and Muscle Function.
Conditions: Hypercholesterolemia
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: 1
Phase: NA
Enrollment: 40
Sponsor: Lescuyer Laboratory
Location: France
Summary
Cardiovascular disease (CVD), foremost among which ischemic heart disease and stroke, are the leading cause of mortality and morbidity in France.
These diseases are multifactorial origin and even if it is not possible to act on risk markers such as age, sex, or heredity, risk factors like high cholesterol, smoking , hypertension, obesity, diabetes and physical inactivity, are the main target of prevention strategies.
Dydlipidemias have a role in the formation of CVD in participating in the genesis of atherosclerosis.
The cholesterol and LDL-cholesterol in particular is subject to oxidation process in plasma.
The molecules of oxidized LDL-cholesterol, small and dense, easily penetrate the arterial endothelial wall and are greeted by macrophages.
Following a succession of different processes including inflammation, atherosclerotic plaque is formed.
The result is either an arteriopathy when the arterial lumen narrowing, or atherothrombosis in the event of plaque rupture.
Given this pathophysiology, reduce blood lipids, including LDL-cholesterol and reducing oxidation and inflammation are interesting strategies in the context of cardiovascular prevention.
Several scientific study showed that nutritional supplementation with some plant extracts such as artichokes, garlic, red yeast rice, or the sugar cane policosanol helps to reduce several cardiovascular risk factors including regulate concentrations of circulating lipids.In this study, we hypothesize that the food supplement LIMICOL contributes to reducing LDL cholesterol in the context of care for patients (dietary measures and physical activity)
Eligibility Criteria
Inclusion Criteria:BMI between 25 and 35 kg/m²Subject has a stable weight for at least three months before the start of the study.LDL ≥ 1.50 g/L0.9 g/L ≤ triglycerides ≤ 4.00 g/LSubject able and willing to comply with the protocol and agreeing to give his informed consent in writing;Subject affiliated with a social security schemeExclusion Criteria:Subject having a confirmed or suspected food allergy, notably to one of the components of the study product;Subject suffering from a severe chronic condition deemed incompatible with participation in the study by the investigatorSubject with glaucomaSubject with uretroprostatic disorderSubjet anxious (score >9 HAD scale)Subject with diabetesSubjet with treatment anticoagulant
Source: ClinicalTrials.gov (NCT05750602). StuddyBuddy aggregates publicly available trial information.